Lukas biomedical Inc.

As of June 30, 2026, Lukas biomedical Inc. carries a market capitalization of 1.05B, placing it among publicly traded companies globally. Its enterprise value stands at 1.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Lukas biomedical Inc. has 41.87M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Lukas biomedical Inc. maintains a current ratio of 0.56, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Lukas biomedical Inc.'s stock has declined approximately 35.77% over the past 52 weeks. The 50-day moving average sits at 19.32, while the 200-day moving average is 24.48.

As of June 30, 2026, Lukas biomedical Inc. holds 26.81M in cash and equivalents against 248.75M in total debt, resulting in a net debt position of 140.81M. Total book value stands at 191.26M, with working capital of -74.51M providing operational flexibility.

Lukas biomedical Inc.'s most recent stock split took place on April 25, 2024.